News|Articles|November 19, 2026

Male Mice Develop More Severe Zika Neurological Disease Despite Comparable Viral Loads

Listen
0:00 / 0:00

Key Takeaways

  • Male Ifnar−/− mice exhibited significantly greater neurologic morbidity than females post-ZIKV infection, while weight loss and viral titers in serum and brain remained equivalent between sexes.
  • Inflammatory quality, not magnitude, diverged: females had higher CD4+ proportions and reduced CD8+ and NKG2D+CD8+ bystander-phenotype T-cell representation within CNS infiltrates.
SHOW MORE

Findings from a McMaster University brief report echo the male-biased severity long documented in influenza and SARS-CoV-2, adding to mounting evidence that biological sex shapes immune responses to viral infection.

Male mice infected with the Zika virus (ZIKV) developed markedly more severe neurological disease than female mice despite carrying comparable amounts of virus in blood and brain tissue, according to a brief report published in The Journal of Infectious Diseases. The findings, from investigators at McMaster University, point to sexually dimorphic immune responses—rather than viral burden—as the driver of that difference, and they add to a growing body of evidence that biological sex is a meaningful variable in infectious disease outcomes.1,2

An Unexpected Signal

The observation emerged by accident. The lab's test cohort at one point included only female mice, and the characteristic neurological symptoms the team had been documenting stopped appearing; when male mice were reintroduced, the symptoms returned. Principal investigator Ali Ashkar, PhD, professor of medicine at McMaster University, said the magnitude of the difference in disease presentation was difficult to reconcile, and first author Alexa Mansour, a doctoral student in the Ashkar lab, said the team initially questioned whether something in its own methods was at fault.2

Study Design and Primary Findings

Investigators infected Ifnar−/− mice on a C57BL/6 background, aged 8 to 16 weeks and age-matched, with 4 × 105 plaque-forming units of ZIKV strain PRVABC-59 by footpad injection. End points were weight loss greater than 20% or hindlimb paralysis, with clinical disease scored on a scale of 0 to 4. Serum was collected at 3 days post-infection (dpi) and brain tissue at 7 dpi, with viral titers quantified by plaque assay.1

Male and female mice lost comparable weight, with no significant differences between groups (n = 14 per group). At 7 dpi, however, males showed a markedly higher incidence and severity of hindlimb weakness or paralysis, while most females were largely protected and only a subset developed mild weakness (P < .001). Viral titers in both serum and brain tissue were high in both sexes, with no significant differences—indicating that the disparity in clinical severity was not explained by viral load.1,2

Immune Profiling Points to Inflammation

Both sexes demonstrated significant lymphocyte infiltration into the central nervous system compared with uninfected controls, and absolute numbers of infiltrating immune cells did not differ significantly by sex. The composition of that infiltrate did differ. Females had a significantly higher proportion of CD4+ T cells and a lower proportion of CD8+ T cells than males, along with significantly fewer NKG2D+CD8+ bystander-phenotype T cells.1

On a 68-plex cytokine and chemokine array performed at 7 dpi (n = 5 per group), males showed higher levels of proinflammatory cytokines and chemokines, whereas females demonstrated an overall lower proinflammatory signature and a distinct cytokine profile. According to Ashkar, "The male immune system seems to respond more strongly to these infections," producing more severe inflammation at the site of infection.1,2

Consistent With Patterns Across Other Viruses

The findings support broader literature documenting male-biased severity in viral infection. Sex chromosome complement and sex steroids have both been implicated in mediating differences in immunity to viruses, including influenza and SARS-CoV-2. In influenza specifically, men are generally more susceptible to severe outcomes, while women more often mount stronger immune responses to infection and vaccination but report more adverse effects—a dynamic with direct relevance for pharmacists counseling individuals on reactogenicity.3,4

Clinical Context and Limitations

ZIKV has not disappeared from circulation. The virus continues to circulate in the Americas as of 2026, though no large outbreaks are currently ongoing, and prior epidemics have been linked to Guillain-Barré syndrome and neurological birth defects that can cause lifelong disability.5

Several limitations constrain interpretation. For example, the investigators noted that their study used only Ifnar−/− mice, which lack type I interferon signaling, and results therefore may not generalize to immunocompetent animals or to humans. A single viral strain, a single inoculation dose, and a single immunologic timepoint were assessed, and the cytokine analysis was limited to 5 animals per group. The authors proposed sex hormones and sex-dependent microglial sensitivity as potential mechanisms but did not test either experimentally.1

Still, the investigators argued that biological sex warrants consideration in infectious disease research and care, noting that male patients may be more susceptible to severe disease.2

REFERENCES
1. Mansour A, Adaimy MJ, Balint E, Montemarano A, Gergis R, Ashkar AA. Biological sex as a determinant of neurological outcomes during Zika virus infection. J Infect Dis. Published online November 5, 2026. doi:10.1093/infdis/jiag544
2. The science behind the "man flu": McMaster Zika study adds to mounting evidence for sex-specific immune responses. News release. EurekAlert! November 16, 2026. Accessed November 18, 2026. https://www.eurekalert.org/news-releases/1152114
3. Jacobsen H, Klein SL. Sex differences in immunity to viral infections. Front Immunol. 2021;12:720952. doi:10.3389/fimmu.2021.720952
4. The influence of sex and gender differences in shaping the immune response to influenza infection and vaccination. Explor Immunol. 2026;6:1003244. doi:10.37349/ei.2026.1003244
5. Pease J. Is Zika still a threat in 2026? University of Florida College of Public Health and Health Professions. June 8, 2026. Accessed November 18, 2026. https://phhp.ufl.edu/2026/06/08/is-zika-still-a-threat-in-2026/

Related to this article